戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ted by the metalloproteinase (MMP) inhibitor batimastat.
2 spase inhibitor and anti-alpha(2) but not by batimastat.
3 atment with the metalloproteinase inhibitor, batimastat.
4  inhibited by the metalloprotease inhibitor, batimastat.
5 is sensitive to a metalloprotease inhibitor, batimastat.
6 pounds such as the metalloprotease inhibitor batimastat ([4-(N-hydroxyamino)-2-(R)-isobutyl-3-(S)-(2-
7 e inhibited following incubation with BB-94 (batimastat), a specific inhibitor of matrix metalloprote
8 olytic activity was inhibited by EDTA and by batimastat, a selective MMP inhibitor.
9                                              Batimastat also reduced the expression of several inflam
10 ntibody to the alpha(2) integrin, but not by batimastat, an inhibitor of MMP-1 enzymatic activity.
11 ent manner by the following synthetic MMPIs: batimastat and marimastat (BB-94 and BB-2516, respective
12 ith two metalloproteinase inhibitors, BB-94 (Batimastat) and GM6001 (Ilomastat), suggesting that the
13 rosine kinase, the metalloprotease inhibitor batimastat, and methyl-beta-cyclodextrin and filipin, wh
14 rved with the PD98059 MEK1 inhibitor and the batimastat (BB-94) inhibitor of MMP activity, but not wi
15 targeted NPs could deliver the MMP inhibitor batimastat (BB-94) to the site of an aneurysm and preven
16          We have examined the interaction of batimastat (BB-94) with a metalloproteinase [atrolysin C
17                    Chronic administration of batimastat (BB-94), a broad spectrum peptide inhibitor o
18 soenzymes or metalloproteinase inhibition by batimastat (BB94) showed that different regulatory signa
19                Other MMP inhibitors, such as Batimastat (British Bio-technology, Oxford, UK), are cur
20 as inhibited by the small molecule inhibitor batimastat but not by tissue inhibitor of metalloproteas
21 ic acid-type metalloprotease inhibitor BB94 (batimastat) but not to tissue inhibitors of metalloprote
22 nhibition ameliorates pathogenesis, and that batimastat could prove to be a significant candidate for
23                                              Batimastat dramatically inhibited the release of soluble
24 eatment with the metalloproteinase inhibitor Batimastat/GM6001, the EGFR phosphorylation inhibitor AG
25 ity, because the metalloproteinase inhibitor batimastat had no effect.
26  in a concentration-dependent fashion, while batimastat increased the surface expression of iCD23.
27 was blocked by the metalloprotease inhibitor batimastat, indicating that autocrine signaling through
28                                The effect of batimastat on cell survival and colony formation was enh
29 y were inhibited by pretreatment with either batimastat or CRM197 or by pretreatment with rapamycin o
30                      Treatment of cells with batimastat or GI254023X, inhibitors of the alpha-secreta
31 r CRM197 or the metalloproteinase inhibitors batimastat or phenanthroline, none of which had any effe
32 a broad spectrum metalloproteinase inhibitor batimastat reduced NT-induced MAP kinase activation.
33        Furthermore, inhibition of MMPs using batimastat reduced the activation of mitogen-activated p
34                            The MMP inhibitor batimastat significantly reduced the GAG release and com
35                       Moreover, treatment of batimastat-treated cells with recombinant sAPPalpha reve
36 on in isometric contraction was increased in batimastat-treated mdx mice compared with those treated
37 ADAM10 brought about similar results, as did batimastat treatment, thereby confirming that APP proces
38 ignaling induced by thrombin is inhibited by batimastat, which suggests a requirement for pro-HB-EGF

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。